MacroGenics (MGNX)
(Delayed Data from NSDQ)
$3.28 USD
-0.11 (-3.24%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $3.29 +0.01 (0.30%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Brokerage Reports
0 items in cart
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 41 - 60 ( 364 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
FDA Rejects Two Partnered Agents in MacroGenics'' Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
FDA Adcom Votes to Delay Retifanlimab Approval Decision; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Second Collaboration Agreement With Zai Lab Inked; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
ASCO 2021 Abstract Roundup for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Investor Focus on MGC018 at ASCO; 1Q21 Financials Reported; Raising to $41
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Retifanlimab Regulatory Progress; 2020 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Retifanlimab Development Milestone Received; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
Retifanlimab Snags Priority Review; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: MacroGenics, Inc.
Industry: Medical - Products
A Quiver Full of Antibody Arrows; Assuming Coverage at Buy and $36 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R